Eloxx Pharmaceuticals Inc. Common Stock (ELOX)

About ELOX

Eloxx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule product candidates that modulate the ribosome and promote readthrough of premature stop codons caused by nonsense mutations in the United States, Israel, and Australia. The company is developing exaluren, a eukaryotic ribosome-selective glycoside in a Phase 2 trial for the treatment of rare kidney diseases, including Alpo…

Employees

10

Website

www.eloxxpharma.com/

Fundamentals

1-day range

$15.07$16.65

Market cap

$74.47M

P/E (trailing)

5.33

P/E (forward)

-21.23

EPS (trailing)

$-7.06

Dividend yield

—

Beta

3.47

Avg. volume

60.8K

Dividend pay date

December 20, 2017

Forecasts

3 analyst ratings

Latest news

• Guggenheim Reiterates Buy on Eloxx Pharma, Maintains $43 Price Target
  benzinga · 8/24/2026
• Guggenheim Reiterates Buy on Eloxx Pharma, Maintains $43 Price Target
  Benzinga · 8/24/2026
• 12 Health Care Stocks Moving In Monday's Pre-Market Session
  Benzinga · 8/24/2026
• 12 Health Care Stocks Moving In Friday's Intraday Session
  Benzinga · 8/21/2026
• LUCID CAPITAL MARKETS Initiates Coverage On Eloxx Pharma with Buy Rating, Announces Price Target of $38
  Benzinga · 8/20/2026

• Domicilium Real Estate Fund III LP · June 10, 2026 · J

  361.6K
• Domicilium Real Estate Fund III LP · June 10, 2026 · J

  238.4K
• Sumit Aggarwal · June 10, 2026 · Grant

  328.8K
• Webster Stephen W · June 8, 2026 · Grant

  13.6K
• Alan Edmund Walts · June 8, 2026 · Grant

  8.6K
• Kjellson Nina S · June 8, 2026 · Grant

  13.6K
• Steven D. Rubin · June 8, 2026 · Grant

  4.0K
• Domicilium Real Estate Fund III LP · May 27, 2026 · J

  113.6K
• Coastlands Capital LP · May 27, 2026 · J

  1.25M